Exact Sciences (NASDAQ:EXAS) Price Target Raised to $75.00

Exact Sciences (NASDAQ:EXAS) had its price objective lifted by Guggenheim from $70.00 to $75.00 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other equities analysts also recently weighed in on EXAS. Royal Bank Of Canada lowered their target price on shares of Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating on the stock in a report on Thursday, August 7th. Stifel Nicolaus raised their price objective on shares of Exact Sciences from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday. Cowen restated a “buy” rating on shares of Exact Sciences in a report on Thursday, August 7th. Craig Hallum boosted their price target on Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Finally, Evercore ISI boosted their price target on Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $73.44.

Exact Sciences Trading Down 3.5%

Shares of NASDAQ:EXAS opened at $67.22 on Tuesday. The company’s 50-day moving average price is $57.71 and its two-hundred day moving average price is $53.24. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56. Exact Sciences has a one year low of $38.81 and a one year high of $72.81. The stock has a market capitalization of $12.73 billion, a PE ratio of -12.38, a price-to-earnings-growth ratio of 5.56 and a beta of 1.34.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business had revenue of $850.74 million for the quarter, compared to analyst estimates of $810.42 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. Exact Sciences’s revenue was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Exact Sciences will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Exact Sciences news, EVP Brian Baranick sold 2,858 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total value of $200,288.64. Following the completion of the transaction, the executive vice president directly owned 22,368 shares in the company, valued at approximately $1,567,549.44. This represents a 11.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the transaction, the director directly owned 57,962 shares of the company’s stock, valued at $3,477,720. The trade was a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,343 shares of company stock worth $382,688 over the last three months. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Exact Sciences by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 17,637,674 shares of the medical research company’s stock worth $763,535,000 after purchasing an additional 617,384 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Exact Sciences by 11.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,403,872 shares of the medical research company’s stock worth $277,225,000 after buying an additional 643,631 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Exact Sciences by 31.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company’s stock worth $213,889,000 after buying an additional 939,888 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Exact Sciences by 12.4% in the first quarter. Mackenzie Financial Corp now owns 3,281,639 shares of the medical research company’s stock valued at $142,062,000 after buying an additional 362,314 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Exact Sciences by 120.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock valued at $135,453,000 after acquiring an additional 1,707,287 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.